Pages that link to "Q28606934"
Jump to navigation
Jump to search
The following pages link to Association of Cardiometabolic Multimorbidity With Mortality (Q28606934):
Displaying 50 items.
- Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile? (Q26740253) (← links)
- Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice (Q26741860) (← links)
- Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes (Q26749281) (← links)
- Psychosocial Factors in Diabetes and Cardiovascular Risk (Q28070388) (← links)
- Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes (Q28072339) (← links)
- Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? (Q30242051) (← links)
- Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data (Q31044439) (← links)
- Mapping the global research landscape and knowledge gaps on multimorbidity: a bibliometric study (Q33810915) (← links)
- Characterization of lipid profile by nuclear magnetic resonance spectroscopy (1H NMR) of metabolically healthy obese women after weight loss with Mediterranean diet and physical exercise. (Q33885701) (← links)
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres (Q34046881) (← links)
- Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis (Q34507164) (← links)
- The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial (Q35924358) (← links)
- Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries (Q36200262) (← links)
- Mortality in Iranian Patients with Parkinson's Disease: Cumulative Impact of Cardiovascular Comorbidities as One Major Risk Factor (Q36242256) (← links)
- Role of the APOE polymorphism in carotid and lower limb revascularization: A prospective study from Southern Italy. (Q36293981) (← links)
- Depression and physical health multimorbidity: primary data and country-wide meta-analysis of population data from 190 593 people across 43 low- and middle-income countries. (Q36333547) (← links)
- Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data (Q36376273) (← links)
- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study (Q36820604) (← links)
- Positive lifestyle changes around the time of pregnancy: a cross-sectional study. (Q36883748) (← links)
- Multimorbidity in Older Patients with Cardiovascular Disease (Q36956600) (← links)
- Transgenerational programming of longevity and reproduction by post-eclosion dietary manipulation in Drosophila (Q37062516) (← links)
- Psycho-socioeconomic bio-behavioral associations on all-cause mortality: cohort study (Q37063409) (← links)
- Obesity, metabolic health, and mortality in adults: a nationwide population-based study in Korea. (Q37117716) (← links)
- The Longitudinal Aging Study Amsterdam: cohort update 2016 and major findings (Q37230553) (← links)
- Hyperglycemia and diabetes have different impacts on outcome of ischemic and hemorrhagic stroke. (Q37549354) (← links)
- Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (Q37594479) (← links)
- Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk (Q37692590) (← links)
- The Role of Healthy Lifestyle in the Implementation of Regressing Suboptimal Health Status among College Students in China: A Nested Case-Control Study (Q37724469) (← links)
- Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cot (Q38376619) (← links)
- Automated Telecommunication Interventions to Promote Adherence to Cardio-metabolic Medications: Meta-analysis of Effectiveness and Meta-regression of Behaviour Change Techniques. (Q38643053) (← links)
- GLP-1 Agonists and Blood Pressure: A Review of the Evidence. (Q38709406) (← links)
- Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants with the General Population. (Q38713566) (← links)
- Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know. (Q38787756) (← links)
- Empagliflozin reduces cardiovascular events and mortality in type 2 diabetes (Q38797667) (← links)
- Advance Care Planning and Goals of Care Communication in Older Adults with Cardiovascular Disease and Multi-Morbidity (Q38817289) (← links)
- Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus (Q38827756) (← links)
- Associations between single and multiple cardiometabolic diseases and cognitive abilities in 474 129 UK Biobank participants (Q38864388) (← links)
- Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus (Q39006105) (← links)
- Renal, metabolic and cardiovascular considerations of SGLT2 inhibition (Q39035951) (← links)
- Cardio-oncology Related to Heart Failure: Common Risk Factors Between Cancer and Cardiovascular Disease (Q39171512) (← links)
- Investigational therapies for hypercholesterolemia (Q39215123) (← links)
- Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor (Q39255963) (← links)
- Two-Year Mortality in Homebound Older Adults: An Analysis of the National Health and Aging Trends Study (Q39377054) (← links)
- Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries (Q39481709) (← links)
- Are major behavioral and sociodemographic risk factors for mortality additive or multiplicative in their effects? (Q39942560) (← links)
- Primary cutaneous B-cell lymphoma and chronic leg ulcers in a patient with type 2 diabetes (Q40189950) (← links)
- Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer. (Q40636362) (← links)
- Risk prediction of major complications in individuals with diabetes: the Atherosclerosis Risk in Communities Study (Q40762736) (← links)
- Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus (Q41242150) (← links)
- Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study (Q41507487) (← links)